Key Takeaways ABT's CGM sales hit $1.9B in Q2 2025, up 19.6% organically, with strong U.S. Libre demand.Diagnostics grew in the United States, Europe and Latin America, despite China VBP and HIV testing cuts.EPD sales rose 7.7% organically, with biosimilar approvals advancing and launches set for 2026.Abbott’s (ABT) diversified business portfolio is well-positioned to drive continued momentum in 2025. Yet, the international business environment continues to be challenging globally. The stock carries a Zacks ...